User login
Remembering three giants in vascular surgery
This year the VEITHsymposium will be paying tribute to three influential vascular surgeons who are no longer with us: Dr. Allan Callow, Dr. Calvin Ernst, and Dr. John (Jack) Connolly.
Dr. Jerry Goldstone, MD, will have the honor of offering his thoughts on these extraordinary gentlemen during a session on Wednesday morning.
“I knew all three of these men quite well at various stages of my career,” Dr. Goldstone said.
Dr. Allan Callow, who died Dec. 22, 2015, at the age of 99, was considered a pioneer in vascular surgery. His contributions to vascular surgery include helping to perfect carotid endarterectomy.
He served in the U.S. Navy during World War II, retiring with the rank of rear admiral and was “an excellent speaker and had accumulated a very large personal experience with carotid artery disease which he was most recognized for as a clinician.”
Dr. Goldstone noted the different career path that this “great role model” followed.
“The most inspirational thing was his late-in-life switch to a basic science career,” Dr. Goldstone said. “Most of us in academics have our most intense basic research very early in our careers, but Allan’s late research career is inspiring and makes so much sense for a variety of reasons, not the least of which is it avoids the physical demands of clinical research.” Dr. Callow received an NIH RO1 grant at a time when contemporaries were retiring, Dr. Goldstone added.
Dr. Calvin Ernst “was probably best known as an educator, author and very dynamic Society of Vascular Surgery,” Dr. Goldstone said. “During his years on the SVS council, he was very actively involved in just about every activity that affected vascular surgery.”
Describing him as a “true Michigan guy” who was born in Detroit and attended the University of Michigan for undergraduate and medical school and stayed on for his surgery residency and then joined the faculty, Dr. Goldstone also remembered his accomplishments outside of SVS.
“Cal was a renowned surgeon and educator,” Dr. Goldstone recalled. “He was a prolific writer, authoring more than 300 papers and books, the best known probably being the first four editions of ‘Current Therapy in Vascular Surgery’ with Dr. James Stanley. ... He also served as the second co-editor of the Journal of Vascular Surgery and played a very important role in the early success of that journal.”
Dr. Ernst retired from practice in 2001 and died July 7, 2015 at the age of 81.
Dr. Goldstone noted that Dr. John (Jack) Connolly’s interests in cardiac and vascular surgery were broad and that he achieved world-wide fame for his presentations and lectures.
“He had a very prominent international influence and received countless invitations to speak abroad.”
He received fellowships were at the Royal College of Surgeons of England, Ireland and Edinburgh, as well as honorary membership in the Japan Vascular Society and the Vascular Surgical Society of Great Britain and Ireland. He also was honored by the University of California Irvine in 2012 when the institution established the John E. Connolly Endowed Chair in Surgery.
Dr. Goldstone remembered how “Jack” was “always a presence during my surgical training and career. Like Dr. Callow, he was still giving talks and writing papers well into his last years of life. He was very active internationally and was a vascular ambassador. He was charming, friendly, always willing to help younger surgeons and always had a genuine smile when he saw you.”
“For many,” Dr. Goldstone continued, “Jack will also be remembered for his friendship and unselfish support and mentoring.”
Dr. Connolly died Jan. 20, 2016, at the age of 92.
Session 34: Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Wednesday, 10:16 a.m. - 10:21 a.m.
Location: Grand Ballroom West, 3rd Floor
This year the VEITHsymposium will be paying tribute to three influential vascular surgeons who are no longer with us: Dr. Allan Callow, Dr. Calvin Ernst, and Dr. John (Jack) Connolly.
Dr. Jerry Goldstone, MD, will have the honor of offering his thoughts on these extraordinary gentlemen during a session on Wednesday morning.
“I knew all three of these men quite well at various stages of my career,” Dr. Goldstone said.
Dr. Allan Callow, who died Dec. 22, 2015, at the age of 99, was considered a pioneer in vascular surgery. His contributions to vascular surgery include helping to perfect carotid endarterectomy.
He served in the U.S. Navy during World War II, retiring with the rank of rear admiral and was “an excellent speaker and had accumulated a very large personal experience with carotid artery disease which he was most recognized for as a clinician.”
Dr. Goldstone noted the different career path that this “great role model” followed.
“The most inspirational thing was his late-in-life switch to a basic science career,” Dr. Goldstone said. “Most of us in academics have our most intense basic research very early in our careers, but Allan’s late research career is inspiring and makes so much sense for a variety of reasons, not the least of which is it avoids the physical demands of clinical research.” Dr. Callow received an NIH RO1 grant at a time when contemporaries were retiring, Dr. Goldstone added.
Dr. Calvin Ernst “was probably best known as an educator, author and very dynamic Society of Vascular Surgery,” Dr. Goldstone said. “During his years on the SVS council, he was very actively involved in just about every activity that affected vascular surgery.”
Describing him as a “true Michigan guy” who was born in Detroit and attended the University of Michigan for undergraduate and medical school and stayed on for his surgery residency and then joined the faculty, Dr. Goldstone also remembered his accomplishments outside of SVS.
“Cal was a renowned surgeon and educator,” Dr. Goldstone recalled. “He was a prolific writer, authoring more than 300 papers and books, the best known probably being the first four editions of ‘Current Therapy in Vascular Surgery’ with Dr. James Stanley. ... He also served as the second co-editor of the Journal of Vascular Surgery and played a very important role in the early success of that journal.”
Dr. Ernst retired from practice in 2001 and died July 7, 2015 at the age of 81.
Dr. Goldstone noted that Dr. John (Jack) Connolly’s interests in cardiac and vascular surgery were broad and that he achieved world-wide fame for his presentations and lectures.
“He had a very prominent international influence and received countless invitations to speak abroad.”
He received fellowships were at the Royal College of Surgeons of England, Ireland and Edinburgh, as well as honorary membership in the Japan Vascular Society and the Vascular Surgical Society of Great Britain and Ireland. He also was honored by the University of California Irvine in 2012 when the institution established the John E. Connolly Endowed Chair in Surgery.
Dr. Goldstone remembered how “Jack” was “always a presence during my surgical training and career. Like Dr. Callow, he was still giving talks and writing papers well into his last years of life. He was very active internationally and was a vascular ambassador. He was charming, friendly, always willing to help younger surgeons and always had a genuine smile when he saw you.”
“For many,” Dr. Goldstone continued, “Jack will also be remembered for his friendship and unselfish support and mentoring.”
Dr. Connolly died Jan. 20, 2016, at the age of 92.
Session 34: Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Wednesday, 10:16 a.m. - 10:21 a.m.
Location: Grand Ballroom West, 3rd Floor
This year the VEITHsymposium will be paying tribute to three influential vascular surgeons who are no longer with us: Dr. Allan Callow, Dr. Calvin Ernst, and Dr. John (Jack) Connolly.
Dr. Jerry Goldstone, MD, will have the honor of offering his thoughts on these extraordinary gentlemen during a session on Wednesday morning.
“I knew all three of these men quite well at various stages of my career,” Dr. Goldstone said.
Dr. Allan Callow, who died Dec. 22, 2015, at the age of 99, was considered a pioneer in vascular surgery. His contributions to vascular surgery include helping to perfect carotid endarterectomy.
He served in the U.S. Navy during World War II, retiring with the rank of rear admiral and was “an excellent speaker and had accumulated a very large personal experience with carotid artery disease which he was most recognized for as a clinician.”
Dr. Goldstone noted the different career path that this “great role model” followed.
“The most inspirational thing was his late-in-life switch to a basic science career,” Dr. Goldstone said. “Most of us in academics have our most intense basic research very early in our careers, but Allan’s late research career is inspiring and makes so much sense for a variety of reasons, not the least of which is it avoids the physical demands of clinical research.” Dr. Callow received an NIH RO1 grant at a time when contemporaries were retiring, Dr. Goldstone added.
Dr. Calvin Ernst “was probably best known as an educator, author and very dynamic Society of Vascular Surgery,” Dr. Goldstone said. “During his years on the SVS council, he was very actively involved in just about every activity that affected vascular surgery.”
Describing him as a “true Michigan guy” who was born in Detroit and attended the University of Michigan for undergraduate and medical school and stayed on for his surgery residency and then joined the faculty, Dr. Goldstone also remembered his accomplishments outside of SVS.
“Cal was a renowned surgeon and educator,” Dr. Goldstone recalled. “He was a prolific writer, authoring more than 300 papers and books, the best known probably being the first four editions of ‘Current Therapy in Vascular Surgery’ with Dr. James Stanley. ... He also served as the second co-editor of the Journal of Vascular Surgery and played a very important role in the early success of that journal.”
Dr. Ernst retired from practice in 2001 and died July 7, 2015 at the age of 81.
Dr. Goldstone noted that Dr. John (Jack) Connolly’s interests in cardiac and vascular surgery were broad and that he achieved world-wide fame for his presentations and lectures.
“He had a very prominent international influence and received countless invitations to speak abroad.”
He received fellowships were at the Royal College of Surgeons of England, Ireland and Edinburgh, as well as honorary membership in the Japan Vascular Society and the Vascular Surgical Society of Great Britain and Ireland. He also was honored by the University of California Irvine in 2012 when the institution established the John E. Connolly Endowed Chair in Surgery.
Dr. Goldstone remembered how “Jack” was “always a presence during my surgical training and career. Like Dr. Callow, he was still giving talks and writing papers well into his last years of life. He was very active internationally and was a vascular ambassador. He was charming, friendly, always willing to help younger surgeons and always had a genuine smile when he saw you.”
“For many,” Dr. Goldstone continued, “Jack will also be remembered for his friendship and unselfish support and mentoring.”
Dr. Connolly died Jan. 20, 2016, at the age of 92.
Session 34: Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Wednesday, 10:16 a.m. - 10:21 a.m.
Location: Grand Ballroom West, 3rd Floor
Carotid Session to Focus on Asymptomatic Disease, Pivotal Trials
A common clinical challenge encountered by vascular surgeons – what to do with asymptomatic carotid artery disease – will be a main focus of the Tuesday afternoon session, “New Key Developments in the Management of Patients with Carotid Disease.”
“Overall, this session will be a look at mostly asymptomatic carotid stenosis, also with some presentations from experts in the field on how to interpret the long-term results of all these trials and incorporate them into your clinical practice. There should be a lot of excitement about this session in light of recent CMS decisions to reimburse for asymptomatic carotid stenosis” in patients who are at high risk for surgery. “That’s a big leap forward,” said moderator Dr. L. Nelson Hopkins of the State University of New York, Buffalo.
The topic of stenting vs. medical therapy will be the topic of two debates. Dr. Kenneth Rosenfield of Harvard Medical School, Boston, will defend the ACT-1 trial, which found that stenting was noninferior to endarterectomy for up to 5 years in asymptomatic patients with severe stenosis; he was lead investigator. Dr. Anne Abbott of Monash University in Melbourne will counter that medical therapy remains the best option.
In another debate, Dr. Thomas G. Brott of the Mayo Clinic in Jacksonville, Fla., the lead investigator on the CREST trial, will argue that 10-year results prove that stenting and endarterectomy are equivalent for both symptomatic and asymptomatic disease; Dr. J. David Spence, of Western University in London, Ontario, will counter that the data can be interpreted in other ways, and that there is a low rate of occlusion and stroke when high-grade asymptomatic stenosis is treated with best medical therapy.
Dr. Andrew Nicolaides of the Imperial College, London, will also share thoughts on identifying asymptomatic patients who benefit from invasive treatment, and Dr. Bruce Perler of Johns Hopkins University, Baltimore, will argue that endarterectomy is the best option.
The session isn’t limited solely to asymptomatic carotid disease. Dr. James May from the University of Sydney is set to share tips and insights about endovascular repair of saccular aneurysms of the extracranial internal carotid. Recent developments have made this repair safer, but fusiform aneurysms remain a challenge. “There’s going to be information about how to treat these lesions with newer technology,” Dr. Hopkins said.
Session 5:
New Key Developments in the Management of Patients with Carotid Disease
Tuesday,1:00 p.m –2:42 p.m.
Grand Ballroom East, 3rd Floor
A common clinical challenge encountered by vascular surgeons – what to do with asymptomatic carotid artery disease – will be a main focus of the Tuesday afternoon session, “New Key Developments in the Management of Patients with Carotid Disease.”
“Overall, this session will be a look at mostly asymptomatic carotid stenosis, also with some presentations from experts in the field on how to interpret the long-term results of all these trials and incorporate them into your clinical practice. There should be a lot of excitement about this session in light of recent CMS decisions to reimburse for asymptomatic carotid stenosis” in patients who are at high risk for surgery. “That’s a big leap forward,” said moderator Dr. L. Nelson Hopkins of the State University of New York, Buffalo.
The topic of stenting vs. medical therapy will be the topic of two debates. Dr. Kenneth Rosenfield of Harvard Medical School, Boston, will defend the ACT-1 trial, which found that stenting was noninferior to endarterectomy for up to 5 years in asymptomatic patients with severe stenosis; he was lead investigator. Dr. Anne Abbott of Monash University in Melbourne will counter that medical therapy remains the best option.
In another debate, Dr. Thomas G. Brott of the Mayo Clinic in Jacksonville, Fla., the lead investigator on the CREST trial, will argue that 10-year results prove that stenting and endarterectomy are equivalent for both symptomatic and asymptomatic disease; Dr. J. David Spence, of Western University in London, Ontario, will counter that the data can be interpreted in other ways, and that there is a low rate of occlusion and stroke when high-grade asymptomatic stenosis is treated with best medical therapy.
Dr. Andrew Nicolaides of the Imperial College, London, will also share thoughts on identifying asymptomatic patients who benefit from invasive treatment, and Dr. Bruce Perler of Johns Hopkins University, Baltimore, will argue that endarterectomy is the best option.
The session isn’t limited solely to asymptomatic carotid disease. Dr. James May from the University of Sydney is set to share tips and insights about endovascular repair of saccular aneurysms of the extracranial internal carotid. Recent developments have made this repair safer, but fusiform aneurysms remain a challenge. “There’s going to be information about how to treat these lesions with newer technology,” Dr. Hopkins said.
Session 5:
New Key Developments in the Management of Patients with Carotid Disease
Tuesday,1:00 p.m –2:42 p.m.
Grand Ballroom East, 3rd Floor
A common clinical challenge encountered by vascular surgeons – what to do with asymptomatic carotid artery disease – will be a main focus of the Tuesday afternoon session, “New Key Developments in the Management of Patients with Carotid Disease.”
“Overall, this session will be a look at mostly asymptomatic carotid stenosis, also with some presentations from experts in the field on how to interpret the long-term results of all these trials and incorporate them into your clinical practice. There should be a lot of excitement about this session in light of recent CMS decisions to reimburse for asymptomatic carotid stenosis” in patients who are at high risk for surgery. “That’s a big leap forward,” said moderator Dr. L. Nelson Hopkins of the State University of New York, Buffalo.
The topic of stenting vs. medical therapy will be the topic of two debates. Dr. Kenneth Rosenfield of Harvard Medical School, Boston, will defend the ACT-1 trial, which found that stenting was noninferior to endarterectomy for up to 5 years in asymptomatic patients with severe stenosis; he was lead investigator. Dr. Anne Abbott of Monash University in Melbourne will counter that medical therapy remains the best option.
In another debate, Dr. Thomas G. Brott of the Mayo Clinic in Jacksonville, Fla., the lead investigator on the CREST trial, will argue that 10-year results prove that stenting and endarterectomy are equivalent for both symptomatic and asymptomatic disease; Dr. J. David Spence, of Western University in London, Ontario, will counter that the data can be interpreted in other ways, and that there is a low rate of occlusion and stroke when high-grade asymptomatic stenosis is treated with best medical therapy.
Dr. Andrew Nicolaides of the Imperial College, London, will also share thoughts on identifying asymptomatic patients who benefit from invasive treatment, and Dr. Bruce Perler of Johns Hopkins University, Baltimore, will argue that endarterectomy is the best option.
The session isn’t limited solely to asymptomatic carotid disease. Dr. James May from the University of Sydney is set to share tips and insights about endovascular repair of saccular aneurysms of the extracranial internal carotid. Recent developments have made this repair safer, but fusiform aneurysms remain a challenge. “There’s going to be information about how to treat these lesions with newer technology,” Dr. Hopkins said.
Session 5:
New Key Developments in the Management of Patients with Carotid Disease
Tuesday,1:00 p.m –2:42 p.m.
Grand Ballroom East, 3rd Floor
Open Surgical Repair Session to Highlight CLI
Attendees at Tuesday afternoon’s “Topics Related to Open Surgery and Aortic Coarctations” session will learn when open surgery is the best choice despite remarkable advances in endovascular treatment.
“There are still open procedures that every vascular surgeon needs to know how to do well,” said moderator Dr. Fred Weaver of the University of Southern California, Los Angeles.
Coral reef lesions, aortoesophageal fistulas, extensive aortobifemoral occlusions, and celiac axis compression syndromes are often just too complex and extensive for endovascular approaches, and endovascular procedures are less likely to work when patients have underlying problems such as Marfan syndrome and Takayasu arteritis. In addition, open fixes for renal artery disease better preserve kidney function, Dr. Weaver noted. They also make sense for young patients needing a durable, one-time fix. “We don’t have much long-term follow-up experience with endovascular procedures, but we have almost a half-century of experience with open vascular procedures. We know how durable they can be,” he said.
Issues surrounding open procedures and more will be addressed in the session. “Open surgical solutions are oftentimes deferred or not even offered for fear of bad outcomes,” but “they can be successful, and you have to have them in your playbook,” said co-moderator Dr. James Black of Johns Hopkins University.
Three presentations will tackle critical limb ischemia (CLI), a “hot topic that is still very controversial,” Dr. Weaver noted.
Dr. Julien Sfeir of Lebanese University, Beirut, will discuss open salvage after failed endovascular CLI intervention. Dr. R. Clement Darling of Albany Medical College in New York, and also a moderator, will discuss the role of open procedures in the endovascular era, and Dr. Carlo Setacci of the University of Siena, Italy, will address combining open and endovascular techniques for especially difficult cases.
BEST-CLI, an ongoing randomized controlled trial comparing endovascular therapy with open surgical bypass in CLI, will likely be discussed, which is “one of the reasons someone might want to come to this session. Nobody really knows what’s the best option in a lot of situations,” Dr. Weaver said.
Dr. Black will also address when open repair is best – and how to do it – when there’s a distal aortic failure after thoracic endovascular aortic repair (TEVAR). “Stents may palliate dissection in the chest, but dissection beyond the stent into the abdomen remains untreated, and there can life-threatening growth of the aortic diameter. Because the dissection anatomy can be so variable, open surgery is the most expeditious fix, especially in a patient with acute symptoms” he said.
One presentation will buck the theme: a new endovascular approach for aortic coarctation. With the recent approval of the NuMED Cheatham Platinum Stent System, “we now have a viable device solution to handle what otherwise would be a major surgery. It’s a very large diameter, balloon-expandable stent graft with significant radial force made to order for this problem. We’ve totally reversed the treatment paradigm, from 10 days in the hospital and 2 months recovery to 1 night in the hospital and you are driving in 2 days,” Dr. Black said.
Yet “whether it works over the long term is an area of considerable uncertainty. This is an area which is in flux,” Dr. Weaver noted. Dr. Elchanan Bruckheimer will speak about the COAST 1 and 2 trials that preceded the Food and Drug Administration approval of the Cheatham Platinum Stent System.
Session 16:
Topics Related to Open Surgery and Aortic Coarctations
Tuesday, 4:32 p.m. – 5:58 p.m.
Grand Ballroom West, 3rd Floor
Attendees at Tuesday afternoon’s “Topics Related to Open Surgery and Aortic Coarctations” session will learn when open surgery is the best choice despite remarkable advances in endovascular treatment.
“There are still open procedures that every vascular surgeon needs to know how to do well,” said moderator Dr. Fred Weaver of the University of Southern California, Los Angeles.
Coral reef lesions, aortoesophageal fistulas, extensive aortobifemoral occlusions, and celiac axis compression syndromes are often just too complex and extensive for endovascular approaches, and endovascular procedures are less likely to work when patients have underlying problems such as Marfan syndrome and Takayasu arteritis. In addition, open fixes for renal artery disease better preserve kidney function, Dr. Weaver noted. They also make sense for young patients needing a durable, one-time fix. “We don’t have much long-term follow-up experience with endovascular procedures, but we have almost a half-century of experience with open vascular procedures. We know how durable they can be,” he said.
Issues surrounding open procedures and more will be addressed in the session. “Open surgical solutions are oftentimes deferred or not even offered for fear of bad outcomes,” but “they can be successful, and you have to have them in your playbook,” said co-moderator Dr. James Black of Johns Hopkins University.
Three presentations will tackle critical limb ischemia (CLI), a “hot topic that is still very controversial,” Dr. Weaver noted.
Dr. Julien Sfeir of Lebanese University, Beirut, will discuss open salvage after failed endovascular CLI intervention. Dr. R. Clement Darling of Albany Medical College in New York, and also a moderator, will discuss the role of open procedures in the endovascular era, and Dr. Carlo Setacci of the University of Siena, Italy, will address combining open and endovascular techniques for especially difficult cases.
BEST-CLI, an ongoing randomized controlled trial comparing endovascular therapy with open surgical bypass in CLI, will likely be discussed, which is “one of the reasons someone might want to come to this session. Nobody really knows what’s the best option in a lot of situations,” Dr. Weaver said.
Dr. Black will also address when open repair is best – and how to do it – when there’s a distal aortic failure after thoracic endovascular aortic repair (TEVAR). “Stents may palliate dissection in the chest, but dissection beyond the stent into the abdomen remains untreated, and there can life-threatening growth of the aortic diameter. Because the dissection anatomy can be so variable, open surgery is the most expeditious fix, especially in a patient with acute symptoms” he said.
One presentation will buck the theme: a new endovascular approach for aortic coarctation. With the recent approval of the NuMED Cheatham Platinum Stent System, “we now have a viable device solution to handle what otherwise would be a major surgery. It’s a very large diameter, balloon-expandable stent graft with significant radial force made to order for this problem. We’ve totally reversed the treatment paradigm, from 10 days in the hospital and 2 months recovery to 1 night in the hospital and you are driving in 2 days,” Dr. Black said.
Yet “whether it works over the long term is an area of considerable uncertainty. This is an area which is in flux,” Dr. Weaver noted. Dr. Elchanan Bruckheimer will speak about the COAST 1 and 2 trials that preceded the Food and Drug Administration approval of the Cheatham Platinum Stent System.
Session 16:
Topics Related to Open Surgery and Aortic Coarctations
Tuesday, 4:32 p.m. – 5:58 p.m.
Grand Ballroom West, 3rd Floor
Attendees at Tuesday afternoon’s “Topics Related to Open Surgery and Aortic Coarctations” session will learn when open surgery is the best choice despite remarkable advances in endovascular treatment.
“There are still open procedures that every vascular surgeon needs to know how to do well,” said moderator Dr. Fred Weaver of the University of Southern California, Los Angeles.
Coral reef lesions, aortoesophageal fistulas, extensive aortobifemoral occlusions, and celiac axis compression syndromes are often just too complex and extensive for endovascular approaches, and endovascular procedures are less likely to work when patients have underlying problems such as Marfan syndrome and Takayasu arteritis. In addition, open fixes for renal artery disease better preserve kidney function, Dr. Weaver noted. They also make sense for young patients needing a durable, one-time fix. “We don’t have much long-term follow-up experience with endovascular procedures, but we have almost a half-century of experience with open vascular procedures. We know how durable they can be,” he said.
Issues surrounding open procedures and more will be addressed in the session. “Open surgical solutions are oftentimes deferred or not even offered for fear of bad outcomes,” but “they can be successful, and you have to have them in your playbook,” said co-moderator Dr. James Black of Johns Hopkins University.
Three presentations will tackle critical limb ischemia (CLI), a “hot topic that is still very controversial,” Dr. Weaver noted.
Dr. Julien Sfeir of Lebanese University, Beirut, will discuss open salvage after failed endovascular CLI intervention. Dr. R. Clement Darling of Albany Medical College in New York, and also a moderator, will discuss the role of open procedures in the endovascular era, and Dr. Carlo Setacci of the University of Siena, Italy, will address combining open and endovascular techniques for especially difficult cases.
BEST-CLI, an ongoing randomized controlled trial comparing endovascular therapy with open surgical bypass in CLI, will likely be discussed, which is “one of the reasons someone might want to come to this session. Nobody really knows what’s the best option in a lot of situations,” Dr. Weaver said.
Dr. Black will also address when open repair is best – and how to do it – when there’s a distal aortic failure after thoracic endovascular aortic repair (TEVAR). “Stents may palliate dissection in the chest, but dissection beyond the stent into the abdomen remains untreated, and there can life-threatening growth of the aortic diameter. Because the dissection anatomy can be so variable, open surgery is the most expeditious fix, especially in a patient with acute symptoms” he said.
One presentation will buck the theme: a new endovascular approach for aortic coarctation. With the recent approval of the NuMED Cheatham Platinum Stent System, “we now have a viable device solution to handle what otherwise would be a major surgery. It’s a very large diameter, balloon-expandable stent graft with significant radial force made to order for this problem. We’ve totally reversed the treatment paradigm, from 10 days in the hospital and 2 months recovery to 1 night in the hospital and you are driving in 2 days,” Dr. Black said.
Yet “whether it works over the long term is an area of considerable uncertainty. This is an area which is in flux,” Dr. Weaver noted. Dr. Elchanan Bruckheimer will speak about the COAST 1 and 2 trials that preceded the Food and Drug Administration approval of the Cheatham Platinum Stent System.
Session 16:
Topics Related to Open Surgery and Aortic Coarctations
Tuesday, 4:32 p.m. – 5:58 p.m.
Grand Ballroom West, 3rd Floor
Identifying the ‘No Option for Treatment’ Patient in Critical Limb Ischemia
Over the last decade, advanced techniques for extreme limb salvage have become available, but are not necessarily preferable for every patient. The focus of the Wednesday afternoon session, “More About CLI: The ‘No Option for Treatment’ Limb and Extreme Limb Salvage Techniques and Results,” is identifying patients for whom limb salvage is a feasible option and those for whom it is not.
“This is an important session, addressing those patients in whom it may be futile to continue pressing for the high-end, complex reconstructions we can perform,” said co-moderator Dr. Richard F. Neville, of the Heart and Vascular Institute in Fairfax, Va.
“There are patients in whom we should just say, ‘Let’s not do four angioplasties, a bypass, and multiple plastic surgeries. The best thing is to give them amputation and rehab them,” said Dr. Neville. The global crisis of type 2 diabetes, the costs and morbidities associated with leg amputation, and mortality rates post amputation have gained the attention of policy makers who have begun pressuring health systems to find less costly alternatives.
“The government has realized what many physicians have known for a while: In the long run, it costs the health care system a lot more to amputate than to save a leg,” said Dr. Neville.
The co-moderator of the session, Dr. Sean P. Lyden of the Cleveland Clinic College of Medicine at Case Western University, argued that new therapies are in high demand. “We still have a lot of patients where our current options of open surgery or endovascular therapy fail [but] too many patients get amputations yearly in the United States. Finding new options for these patients is critical.”
The typical VEITHsymposium attendee is well aware that limbs can be salvaged, but there is a lack of awareness of the range of possibilities for critical limb ischemia across most other specialties. “We vascular surgeons know it’s possible, but we have to get the word out to the primary care doctors, the endocrinologists, and others to let them know that this can be done,” said Dr. Neville.
The criteria for which patients make the best candidates for extreme limb salvage are still evolving. “It’s harder than you think,” said Dr. Neville. “There are many different opinions about what should even go into the decision-making process. Even thought leaders from vascular surgery, podiatry, and plastic surgery are struggling to decide on what factors are most implicated. It’s not that the specialties are in disagreement, but we can’t quite come to a consensus yet.”
Data surrounding critical limb ischemia outcomes will be discussed at the session, and the panel will debate what are the best criteria for determining extreme limb salvation algorithms.
“If we could come up with guidelines or a scoring system, that would allow us to have a helpful tool when discussing treatment options with the patient’s family who typically want us to do everything, even when we know it’s not the best thing to do,” said Dr. Neville.
Session 27:
More About CLI: The ‘No Option for Treatment’ Limb and Extreme Limb Salvage Techniques nd Results
Wednesday, 1:00 p.m. – 2:06 p.m.
Grand Ballroom East, 3rd Floor
Over the last decade, advanced techniques for extreme limb salvage have become available, but are not necessarily preferable for every patient. The focus of the Wednesday afternoon session, “More About CLI: The ‘No Option for Treatment’ Limb and Extreme Limb Salvage Techniques and Results,” is identifying patients for whom limb salvage is a feasible option and those for whom it is not.
“This is an important session, addressing those patients in whom it may be futile to continue pressing for the high-end, complex reconstructions we can perform,” said co-moderator Dr. Richard F. Neville, of the Heart and Vascular Institute in Fairfax, Va.
“There are patients in whom we should just say, ‘Let’s not do four angioplasties, a bypass, and multiple plastic surgeries. The best thing is to give them amputation and rehab them,” said Dr. Neville. The global crisis of type 2 diabetes, the costs and morbidities associated with leg amputation, and mortality rates post amputation have gained the attention of policy makers who have begun pressuring health systems to find less costly alternatives.
“The government has realized what many physicians have known for a while: In the long run, it costs the health care system a lot more to amputate than to save a leg,” said Dr. Neville.
The co-moderator of the session, Dr. Sean P. Lyden of the Cleveland Clinic College of Medicine at Case Western University, argued that new therapies are in high demand. “We still have a lot of patients where our current options of open surgery or endovascular therapy fail [but] too many patients get amputations yearly in the United States. Finding new options for these patients is critical.”
The typical VEITHsymposium attendee is well aware that limbs can be salvaged, but there is a lack of awareness of the range of possibilities for critical limb ischemia across most other specialties. “We vascular surgeons know it’s possible, but we have to get the word out to the primary care doctors, the endocrinologists, and others to let them know that this can be done,” said Dr. Neville.
The criteria for which patients make the best candidates for extreme limb salvage are still evolving. “It’s harder than you think,” said Dr. Neville. “There are many different opinions about what should even go into the decision-making process. Even thought leaders from vascular surgery, podiatry, and plastic surgery are struggling to decide on what factors are most implicated. It’s not that the specialties are in disagreement, but we can’t quite come to a consensus yet.”
Data surrounding critical limb ischemia outcomes will be discussed at the session, and the panel will debate what are the best criteria for determining extreme limb salvation algorithms.
“If we could come up with guidelines or a scoring system, that would allow us to have a helpful tool when discussing treatment options with the patient’s family who typically want us to do everything, even when we know it’s not the best thing to do,” said Dr. Neville.
Session 27:
More About CLI: The ‘No Option for Treatment’ Limb and Extreme Limb Salvage Techniques nd Results
Wednesday, 1:00 p.m. – 2:06 p.m.
Grand Ballroom East, 3rd Floor
Over the last decade, advanced techniques for extreme limb salvage have become available, but are not necessarily preferable for every patient. The focus of the Wednesday afternoon session, “More About CLI: The ‘No Option for Treatment’ Limb and Extreme Limb Salvage Techniques and Results,” is identifying patients for whom limb salvage is a feasible option and those for whom it is not.
“This is an important session, addressing those patients in whom it may be futile to continue pressing for the high-end, complex reconstructions we can perform,” said co-moderator Dr. Richard F. Neville, of the Heart and Vascular Institute in Fairfax, Va.
“There are patients in whom we should just say, ‘Let’s not do four angioplasties, a bypass, and multiple plastic surgeries. The best thing is to give them amputation and rehab them,” said Dr. Neville. The global crisis of type 2 diabetes, the costs and morbidities associated with leg amputation, and mortality rates post amputation have gained the attention of policy makers who have begun pressuring health systems to find less costly alternatives.
“The government has realized what many physicians have known for a while: In the long run, it costs the health care system a lot more to amputate than to save a leg,” said Dr. Neville.
The co-moderator of the session, Dr. Sean P. Lyden of the Cleveland Clinic College of Medicine at Case Western University, argued that new therapies are in high demand. “We still have a lot of patients where our current options of open surgery or endovascular therapy fail [but] too many patients get amputations yearly in the United States. Finding new options for these patients is critical.”
The typical VEITHsymposium attendee is well aware that limbs can be salvaged, but there is a lack of awareness of the range of possibilities for critical limb ischemia across most other specialties. “We vascular surgeons know it’s possible, but we have to get the word out to the primary care doctors, the endocrinologists, and others to let them know that this can be done,” said Dr. Neville.
The criteria for which patients make the best candidates for extreme limb salvage are still evolving. “It’s harder than you think,” said Dr. Neville. “There are many different opinions about what should even go into the decision-making process. Even thought leaders from vascular surgery, podiatry, and plastic surgery are struggling to decide on what factors are most implicated. It’s not that the specialties are in disagreement, but we can’t quite come to a consensus yet.”
Data surrounding critical limb ischemia outcomes will be discussed at the session, and the panel will debate what are the best criteria for determining extreme limb salvation algorithms.
“If we could come up with guidelines or a scoring system, that would allow us to have a helpful tool when discussing treatment options with the patient’s family who typically want us to do everything, even when we know it’s not the best thing to do,” said Dr. Neville.
Session 27:
More About CLI: The ‘No Option for Treatment’ Limb and Extreme Limb Salvage Techniques nd Results
Wednesday, 1:00 p.m. – 2:06 p.m.
Grand Ballroom East, 3rd Floor
Take a Bite of the Big Apple at the VEITHsymposium
New York City is a global destination renowned for its unparalleled variety of things to do and see to match all tastes and interests. In your time between and after the VEITHsymposium sessions, you can enjoy a Broadway show, take in some of the city’s famous museums, go on a shopping spree, or dine at some of the best restaurants in the world. Whether with family or on your own, there is something for everyone.
For a quick look at current entertainment and dining options, pick up a copy of TimeOut New York or visit www.timeout.com/newyork, where you’ll find current listings for what is playing at theaters off and on Broadway as well as live music, special events, shopping, fine dining, and more.
For a more comprehensive listing of Broadway and off-Broadway shows, visit www.Broadway.com.
For the sports fan, you can find a complete online calendar listing of sporting events that are going during the VEITHsymposium (www.nycgo.com/things-to-do/events-in-nyc/sports-calendar). Pick up the New York Knicks basketball team playing the Detroit Pistons on Nov. 16 at Madison Square Garden. College basketball will also be featured at the Garden with the Champions Classic on Nov. 15.
If you’re a classical music enthusiast, you should make time to attend a performance at Lincoln Center (www.lincolncenter.org), which plays host to the New York Philharmonic and the Metropolitan Opera. During the VEITHsymposium, the operas “Aida,” “La Boheme,” and “Manon Lescaut” are all being performed.
And for the forever young crowd, Billy Joel is in concert at Madison Square Garden on Nov. 19.
No matter where your music tastes lie, for the most up-to-date accounting of musical performances in the city, pick up a copy of the free weekly newspaper, the Village Voice, or visit it online (www.villagevoice.com).
For your exercise pleasure and a literal change of pace, there are a number of interesting walking tours available, including ones that amble through the historic lower East Side, the Metropolitan Opera, and Broadway theaters (www.walksofnewyork.com).
The New York food scene is both vast and varied, so to choose your dining from fine to fun, you can visit the venerable New York Times website (www.nytimes.com/reviews/dining) to plan your eating experience by rating, price, neighborhood, and choice of cuisine.
You will find several notable museums and landmarks within a few blocks of the VEITHsymposium. The Museum of Modern Art is the closest to the New York Hilton Midtown, at 11 West 53rd St., between Fifth and Sixth Avenues. MoMA houses more than 150,000 paintings, sculptures, drawings, prints, photographs, architectural models and drawings, and design objects. The Metropolitan Museum of Art is a bit farther away (1000 Fifth Ave. at 82nd St.). The holdings include 2 million works spanning 5,000 years of art history from around the world from Egyptian mummies to Rembrandts and Picassos.
The American Museum of Natural History is on the Upper West Side of Central Park (at 79th St.) and has something for museum goers of all ages: dinosaurs, fossils, stuffed specimens, minerals, gems, and human cultural artifacts.
The memorial at the site of the World Trade Center towers stands witness to a national tragedy and to the spirit of the people of New York. The names of nearly 3,000 men, women, and children killed in the attacks of Sept. 11, 2001, and Feb. 26, 1993, are inscribed on the parapets surrounding the two memorial pools (www.911memorial.org/visit).
In addition the famous Central Park, don’t overlook the less-noted Bryant Park (between 40th and 42nd Streets and Fifth and Sixth Avenues), which offers an opportunity to do some holiday shopping at the annual Holiday Shops fair. This outdoor, European-style market features everything from handcrafted items to gourmet treats.
If you’re a first-time visitor, the Empire State Building, the Statue of Liberty, and Ellis Island remain the must-see symbols of New York. Be prepared for long lines to get to the top of the Empire State Building (www.esbnyc.com). Dress warmly for the ferry ride from Battery Park (www.statuecruises.com) to the Statue of Liberty.
Above all, while you’re at the VEITHsymposium, be sure that you and your guests enjoy some of the many pleasures that New York has to offer. It’s your kind of town.
New York City is a global destination renowned for its unparalleled variety of things to do and see to match all tastes and interests. In your time between and after the VEITHsymposium sessions, you can enjoy a Broadway show, take in some of the city’s famous museums, go on a shopping spree, or dine at some of the best restaurants in the world. Whether with family or on your own, there is something for everyone.
For a quick look at current entertainment and dining options, pick up a copy of TimeOut New York or visit www.timeout.com/newyork, where you’ll find current listings for what is playing at theaters off and on Broadway as well as live music, special events, shopping, fine dining, and more.
For a more comprehensive listing of Broadway and off-Broadway shows, visit www.Broadway.com.
For the sports fan, you can find a complete online calendar listing of sporting events that are going during the VEITHsymposium (www.nycgo.com/things-to-do/events-in-nyc/sports-calendar). Pick up the New York Knicks basketball team playing the Detroit Pistons on Nov. 16 at Madison Square Garden. College basketball will also be featured at the Garden with the Champions Classic on Nov. 15.
If you’re a classical music enthusiast, you should make time to attend a performance at Lincoln Center (www.lincolncenter.org), which plays host to the New York Philharmonic and the Metropolitan Opera. During the VEITHsymposium, the operas “Aida,” “La Boheme,” and “Manon Lescaut” are all being performed.
And for the forever young crowd, Billy Joel is in concert at Madison Square Garden on Nov. 19.
No matter where your music tastes lie, for the most up-to-date accounting of musical performances in the city, pick up a copy of the free weekly newspaper, the Village Voice, or visit it online (www.villagevoice.com).
For your exercise pleasure and a literal change of pace, there are a number of interesting walking tours available, including ones that amble through the historic lower East Side, the Metropolitan Opera, and Broadway theaters (www.walksofnewyork.com).
The New York food scene is both vast and varied, so to choose your dining from fine to fun, you can visit the venerable New York Times website (www.nytimes.com/reviews/dining) to plan your eating experience by rating, price, neighborhood, and choice of cuisine.
You will find several notable museums and landmarks within a few blocks of the VEITHsymposium. The Museum of Modern Art is the closest to the New York Hilton Midtown, at 11 West 53rd St., between Fifth and Sixth Avenues. MoMA houses more than 150,000 paintings, sculptures, drawings, prints, photographs, architectural models and drawings, and design objects. The Metropolitan Museum of Art is a bit farther away (1000 Fifth Ave. at 82nd St.). The holdings include 2 million works spanning 5,000 years of art history from around the world from Egyptian mummies to Rembrandts and Picassos.
The American Museum of Natural History is on the Upper West Side of Central Park (at 79th St.) and has something for museum goers of all ages: dinosaurs, fossils, stuffed specimens, minerals, gems, and human cultural artifacts.
The memorial at the site of the World Trade Center towers stands witness to a national tragedy and to the spirit of the people of New York. The names of nearly 3,000 men, women, and children killed in the attacks of Sept. 11, 2001, and Feb. 26, 1993, are inscribed on the parapets surrounding the two memorial pools (www.911memorial.org/visit).
In addition the famous Central Park, don’t overlook the less-noted Bryant Park (between 40th and 42nd Streets and Fifth and Sixth Avenues), which offers an opportunity to do some holiday shopping at the annual Holiday Shops fair. This outdoor, European-style market features everything from handcrafted items to gourmet treats.
If you’re a first-time visitor, the Empire State Building, the Statue of Liberty, and Ellis Island remain the must-see symbols of New York. Be prepared for long lines to get to the top of the Empire State Building (www.esbnyc.com). Dress warmly for the ferry ride from Battery Park (www.statuecruises.com) to the Statue of Liberty.
Above all, while you’re at the VEITHsymposium, be sure that you and your guests enjoy some of the many pleasures that New York has to offer. It’s your kind of town.
New York City is a global destination renowned for its unparalleled variety of things to do and see to match all tastes and interests. In your time between and after the VEITHsymposium sessions, you can enjoy a Broadway show, take in some of the city’s famous museums, go on a shopping spree, or dine at some of the best restaurants in the world. Whether with family or on your own, there is something for everyone.
For a quick look at current entertainment and dining options, pick up a copy of TimeOut New York or visit www.timeout.com/newyork, where you’ll find current listings for what is playing at theaters off and on Broadway as well as live music, special events, shopping, fine dining, and more.
For a more comprehensive listing of Broadway and off-Broadway shows, visit www.Broadway.com.
For the sports fan, you can find a complete online calendar listing of sporting events that are going during the VEITHsymposium (www.nycgo.com/things-to-do/events-in-nyc/sports-calendar). Pick up the New York Knicks basketball team playing the Detroit Pistons on Nov. 16 at Madison Square Garden. College basketball will also be featured at the Garden with the Champions Classic on Nov. 15.
If you’re a classical music enthusiast, you should make time to attend a performance at Lincoln Center (www.lincolncenter.org), which plays host to the New York Philharmonic and the Metropolitan Opera. During the VEITHsymposium, the operas “Aida,” “La Boheme,” and “Manon Lescaut” are all being performed.
And for the forever young crowd, Billy Joel is in concert at Madison Square Garden on Nov. 19.
No matter where your music tastes lie, for the most up-to-date accounting of musical performances in the city, pick up a copy of the free weekly newspaper, the Village Voice, or visit it online (www.villagevoice.com).
For your exercise pleasure and a literal change of pace, there are a number of interesting walking tours available, including ones that amble through the historic lower East Side, the Metropolitan Opera, and Broadway theaters (www.walksofnewyork.com).
The New York food scene is both vast and varied, so to choose your dining from fine to fun, you can visit the venerable New York Times website (www.nytimes.com/reviews/dining) to plan your eating experience by rating, price, neighborhood, and choice of cuisine.
You will find several notable museums and landmarks within a few blocks of the VEITHsymposium. The Museum of Modern Art is the closest to the New York Hilton Midtown, at 11 West 53rd St., between Fifth and Sixth Avenues. MoMA houses more than 150,000 paintings, sculptures, drawings, prints, photographs, architectural models and drawings, and design objects. The Metropolitan Museum of Art is a bit farther away (1000 Fifth Ave. at 82nd St.). The holdings include 2 million works spanning 5,000 years of art history from around the world from Egyptian mummies to Rembrandts and Picassos.
The American Museum of Natural History is on the Upper West Side of Central Park (at 79th St.) and has something for museum goers of all ages: dinosaurs, fossils, stuffed specimens, minerals, gems, and human cultural artifacts.
The memorial at the site of the World Trade Center towers stands witness to a national tragedy and to the spirit of the people of New York. The names of nearly 3,000 men, women, and children killed in the attacks of Sept. 11, 2001, and Feb. 26, 1993, are inscribed on the parapets surrounding the two memorial pools (www.911memorial.org/visit).
In addition the famous Central Park, don’t overlook the less-noted Bryant Park (between 40th and 42nd Streets and Fifth and Sixth Avenues), which offers an opportunity to do some holiday shopping at the annual Holiday Shops fair. This outdoor, European-style market features everything from handcrafted items to gourmet treats.
If you’re a first-time visitor, the Empire State Building, the Statue of Liberty, and Ellis Island remain the must-see symbols of New York. Be prepared for long lines to get to the top of the Empire State Building (www.esbnyc.com). Dress warmly for the ferry ride from Battery Park (www.statuecruises.com) to the Statue of Liberty.
Above all, while you’re at the VEITHsymposium, be sure that you and your guests enjoy some of the many pleasures that New York has to offer. It’s your kind of town.
Welcome to the 2016 VEITHsymposium
Welcome to the 43rd annual Vascular & Endovascular, Issues, Techniques and Horizons Symposium (VEITHsymposium). This year’s program promises to be one of the best, most comprehensive, and most thought-provoking of any of our meetings. This year we celebrate our 43rd anniversary and have introduced several improvements.
Nearly 600 international clinician/educators have gathered to provide attendees with the latest topics and advances that are important to the global vascular community. These data span the breadth of vascular diseases, diagnostic procedures, medical treatments, interventional procedures and open surgical advances for treating vascular disease. As is the hallmark of the VEITHsymposium, the 5-day program will run from dawn to dusk daily and will be fully captured in our online library.
Top vascular experts from around the world will provide updates on the latest clinical trials and offer insight into the real-life application of the most recent data to close the gap between the current state of knowledge and actual clinical practice.
Controversial issues will be approached from multiple perspectives to ensure a balanced, unbiased exposure of topics and to provide audience members with the information they need to make informed choices in their own practices.
This year our meeting continues its increased emphasis on venous disease. Three full days of the meeting are developments in venous disease of all sorts and active endovascular treatments in this rapidly expanding area of opportunity.
Some of the program’s other hot topics will be the continuing controversies surrounding parallel grafts (chimneys, and snorkel and sandwich grafts); multilayer open stents versus fenestrated and branched endografts; new developments in carotid stenting; new developments in the treatment of aortic dissections; a day devoted to the management of arteriovenous malformations (AVMs); new developments in the endovascular treatment of lower-extremity ischemia, particularly below the knee; the latest developments in EVAR and TEVAR including experiences with a plethora of new endovascular grafts and devices that have appeared on the scene in the last year; and improvements in the medical treatment of vascular disease and vascular patients undergoing surgery and other interventions. Important issues to vascular specialists and outpatient vascular treatment will also be highlighted.
This year’s program will include a special session all-day Tuesday, focused in the morning on management options for pulmonary embolism led by Dr. Michael R. Jaff. The afternoon part of the day will focus on new developments in the management of acute and chronic large vein occlusion, and will be led by Dr. Kenneth Ouriel.
This year there will also be sessions devoted to crucial issues for vascular specialists including changing relationships with government and the FDA and how to survive under new reimbursement rules and regulations including Obamacare. Our physician/educators will also offer a glimpse into some new techniques and technologies that have been available overseas, but are just gaining approval in the United States, such as drug-eluting balloons and stents.
Attendees will notice some other exciting changes or additions to this year’s program. We have included a new Job Fair Program on Friday in the Americas Hall 1 on the 3rd floor. In addition, there will be more breaks in the schedule to encourage exploration of state-of-the-art technology, products, and services available in the Exhibit areas and Pavilions. The Exhibit Halls are crowded with displays and booths of particular interest to vascular surgeons and vascular specialists. The Pavilions and Exhibits also offer attendees the chance to meet faculty and to network with other attendees and industry partners. This is one place to learn more about exciting new technologies and developments in our field.
Other new additions to our meeting this year will be an exciting Abbott Pavilion in the Americas Hall as well as an expanded Innovations and Investment Summit which facilitates interaction between innovators, industry and investors. This non-CME Session will be held from 8 AM to 3 PM on Thursday, November 17th in the Gramercy Suites on the 2nd floor, and will be led by Kenneth Ouriel, Jean Bismuth and Chris Cheng.
Also new this year will be an expanded VEITHsymposium mobile app, provided courtesy of Cook Medical. Download the app for your iPhone, iPad or Android phone or tablet! Search the App Store (iPhone/iPad) or Google Play Store (Android) for “VEITHsymposium 2016” and install the app. You will be able to access the complete program, create your personal program, add your notes, view the location of sessions and exhibitors on the floor plan, and much more. After you have installed the app and opened it for the first time, you can continue to use it offline. To receive the latest updates and announcements, you will need to be connected to the internet.
In addition, there will be expanded Associate Faculty programs which will give younger and less well-known vascular specialists the opportunity to present their work at the podium with leading experts as session moderators.
Again this year, an Online Library will be available for a minimal fee of $75 for clinical meeting attendees and will include access to talks, slides, videos, and panels from the meeting. This Library will enable all attendees to see and hear key presentations they may miss because of the concurrent sessions or other reasons. This library will be available 10-14 days after the meeting. Attendees should note in their program talks they wish to hear but could not, and then revisit the missed talks on the Online Library which is indexed exactly to the program. The talks are also indexed in the Library by presenter, topic, or session. This Library is a great resource for study, research or review for any purpose.
On behalf of all the meeting Co-Chairmen and our entire staff, we greatly appreciate you coming to our meeting. We hope it is our best meeting ever and that you find it educational, most useful and exciting so that you return next year.
Welcome to the 43rd annual Vascular & Endovascular, Issues, Techniques and Horizons Symposium (VEITHsymposium). This year’s program promises to be one of the best, most comprehensive, and most thought-provoking of any of our meetings. This year we celebrate our 43rd anniversary and have introduced several improvements.
Nearly 600 international clinician/educators have gathered to provide attendees with the latest topics and advances that are important to the global vascular community. These data span the breadth of vascular diseases, diagnostic procedures, medical treatments, interventional procedures and open surgical advances for treating vascular disease. As is the hallmark of the VEITHsymposium, the 5-day program will run from dawn to dusk daily and will be fully captured in our online library.
Top vascular experts from around the world will provide updates on the latest clinical trials and offer insight into the real-life application of the most recent data to close the gap between the current state of knowledge and actual clinical practice.
Controversial issues will be approached from multiple perspectives to ensure a balanced, unbiased exposure of topics and to provide audience members with the information they need to make informed choices in their own practices.
This year our meeting continues its increased emphasis on venous disease. Three full days of the meeting are developments in venous disease of all sorts and active endovascular treatments in this rapidly expanding area of opportunity.
Some of the program’s other hot topics will be the continuing controversies surrounding parallel grafts (chimneys, and snorkel and sandwich grafts); multilayer open stents versus fenestrated and branched endografts; new developments in carotid stenting; new developments in the treatment of aortic dissections; a day devoted to the management of arteriovenous malformations (AVMs); new developments in the endovascular treatment of lower-extremity ischemia, particularly below the knee; the latest developments in EVAR and TEVAR including experiences with a plethora of new endovascular grafts and devices that have appeared on the scene in the last year; and improvements in the medical treatment of vascular disease and vascular patients undergoing surgery and other interventions. Important issues to vascular specialists and outpatient vascular treatment will also be highlighted.
This year’s program will include a special session all-day Tuesday, focused in the morning on management options for pulmonary embolism led by Dr. Michael R. Jaff. The afternoon part of the day will focus on new developments in the management of acute and chronic large vein occlusion, and will be led by Dr. Kenneth Ouriel.
This year there will also be sessions devoted to crucial issues for vascular specialists including changing relationships with government and the FDA and how to survive under new reimbursement rules and regulations including Obamacare. Our physician/educators will also offer a glimpse into some new techniques and technologies that have been available overseas, but are just gaining approval in the United States, such as drug-eluting balloons and stents.
Attendees will notice some other exciting changes or additions to this year’s program. We have included a new Job Fair Program on Friday in the Americas Hall 1 on the 3rd floor. In addition, there will be more breaks in the schedule to encourage exploration of state-of-the-art technology, products, and services available in the Exhibit areas and Pavilions. The Exhibit Halls are crowded with displays and booths of particular interest to vascular surgeons and vascular specialists. The Pavilions and Exhibits also offer attendees the chance to meet faculty and to network with other attendees and industry partners. This is one place to learn more about exciting new technologies and developments in our field.
Other new additions to our meeting this year will be an exciting Abbott Pavilion in the Americas Hall as well as an expanded Innovations and Investment Summit which facilitates interaction between innovators, industry and investors. This non-CME Session will be held from 8 AM to 3 PM on Thursday, November 17th in the Gramercy Suites on the 2nd floor, and will be led by Kenneth Ouriel, Jean Bismuth and Chris Cheng.
Also new this year will be an expanded VEITHsymposium mobile app, provided courtesy of Cook Medical. Download the app for your iPhone, iPad or Android phone or tablet! Search the App Store (iPhone/iPad) or Google Play Store (Android) for “VEITHsymposium 2016” and install the app. You will be able to access the complete program, create your personal program, add your notes, view the location of sessions and exhibitors on the floor plan, and much more. After you have installed the app and opened it for the first time, you can continue to use it offline. To receive the latest updates and announcements, you will need to be connected to the internet.
In addition, there will be expanded Associate Faculty programs which will give younger and less well-known vascular specialists the opportunity to present their work at the podium with leading experts as session moderators.
Again this year, an Online Library will be available for a minimal fee of $75 for clinical meeting attendees and will include access to talks, slides, videos, and panels from the meeting. This Library will enable all attendees to see and hear key presentations they may miss because of the concurrent sessions or other reasons. This library will be available 10-14 days after the meeting. Attendees should note in their program talks they wish to hear but could not, and then revisit the missed talks on the Online Library which is indexed exactly to the program. The talks are also indexed in the Library by presenter, topic, or session. This Library is a great resource for study, research or review for any purpose.
On behalf of all the meeting Co-Chairmen and our entire staff, we greatly appreciate you coming to our meeting. We hope it is our best meeting ever and that you find it educational, most useful and exciting so that you return next year.
Welcome to the 43rd annual Vascular & Endovascular, Issues, Techniques and Horizons Symposium (VEITHsymposium). This year’s program promises to be one of the best, most comprehensive, and most thought-provoking of any of our meetings. This year we celebrate our 43rd anniversary and have introduced several improvements.
Nearly 600 international clinician/educators have gathered to provide attendees with the latest topics and advances that are important to the global vascular community. These data span the breadth of vascular diseases, diagnostic procedures, medical treatments, interventional procedures and open surgical advances for treating vascular disease. As is the hallmark of the VEITHsymposium, the 5-day program will run from dawn to dusk daily and will be fully captured in our online library.
Top vascular experts from around the world will provide updates on the latest clinical trials and offer insight into the real-life application of the most recent data to close the gap between the current state of knowledge and actual clinical practice.
Controversial issues will be approached from multiple perspectives to ensure a balanced, unbiased exposure of topics and to provide audience members with the information they need to make informed choices in their own practices.
This year our meeting continues its increased emphasis on venous disease. Three full days of the meeting are developments in venous disease of all sorts and active endovascular treatments in this rapidly expanding area of opportunity.
Some of the program’s other hot topics will be the continuing controversies surrounding parallel grafts (chimneys, and snorkel and sandwich grafts); multilayer open stents versus fenestrated and branched endografts; new developments in carotid stenting; new developments in the treatment of aortic dissections; a day devoted to the management of arteriovenous malformations (AVMs); new developments in the endovascular treatment of lower-extremity ischemia, particularly below the knee; the latest developments in EVAR and TEVAR including experiences with a plethora of new endovascular grafts and devices that have appeared on the scene in the last year; and improvements in the medical treatment of vascular disease and vascular patients undergoing surgery and other interventions. Important issues to vascular specialists and outpatient vascular treatment will also be highlighted.
This year’s program will include a special session all-day Tuesday, focused in the morning on management options for pulmonary embolism led by Dr. Michael R. Jaff. The afternoon part of the day will focus on new developments in the management of acute and chronic large vein occlusion, and will be led by Dr. Kenneth Ouriel.
This year there will also be sessions devoted to crucial issues for vascular specialists including changing relationships with government and the FDA and how to survive under new reimbursement rules and regulations including Obamacare. Our physician/educators will also offer a glimpse into some new techniques and technologies that have been available overseas, but are just gaining approval in the United States, such as drug-eluting balloons and stents.
Attendees will notice some other exciting changes or additions to this year’s program. We have included a new Job Fair Program on Friday in the Americas Hall 1 on the 3rd floor. In addition, there will be more breaks in the schedule to encourage exploration of state-of-the-art technology, products, and services available in the Exhibit areas and Pavilions. The Exhibit Halls are crowded with displays and booths of particular interest to vascular surgeons and vascular specialists. The Pavilions and Exhibits also offer attendees the chance to meet faculty and to network with other attendees and industry partners. This is one place to learn more about exciting new technologies and developments in our field.
Other new additions to our meeting this year will be an exciting Abbott Pavilion in the Americas Hall as well as an expanded Innovations and Investment Summit which facilitates interaction between innovators, industry and investors. This non-CME Session will be held from 8 AM to 3 PM on Thursday, November 17th in the Gramercy Suites on the 2nd floor, and will be led by Kenneth Ouriel, Jean Bismuth and Chris Cheng.
Also new this year will be an expanded VEITHsymposium mobile app, provided courtesy of Cook Medical. Download the app for your iPhone, iPad or Android phone or tablet! Search the App Store (iPhone/iPad) or Google Play Store (Android) for “VEITHsymposium 2016” and install the app. You will be able to access the complete program, create your personal program, add your notes, view the location of sessions and exhibitors on the floor plan, and much more. After you have installed the app and opened it for the first time, you can continue to use it offline. To receive the latest updates and announcements, you will need to be connected to the internet.
In addition, there will be expanded Associate Faculty programs which will give younger and less well-known vascular specialists the opportunity to present their work at the podium with leading experts as session moderators.
Again this year, an Online Library will be available for a minimal fee of $75 for clinical meeting attendees and will include access to talks, slides, videos, and panels from the meeting. This Library will enable all attendees to see and hear key presentations they may miss because of the concurrent sessions or other reasons. This library will be available 10-14 days after the meeting. Attendees should note in their program talks they wish to hear but could not, and then revisit the missed talks on the Online Library which is indexed exactly to the program. The talks are also indexed in the Library by presenter, topic, or session. This Library is a great resource for study, research or review for any purpose.
On behalf of all the meeting Co-Chairmen and our entire staff, we greatly appreciate you coming to our meeting. We hope it is our best meeting ever and that you find it educational, most useful and exciting so that you return next year.